Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma.

[1]  M. Srougi,et al.  Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup. , 1994, The Journal of urology.

[2]  C. Sternberg,et al.  Neoadjuvant m‐vac (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder , 1993, Cancer.

[3]  W. Shipley,et al.  Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Raghavan.  Chemotherapy for advanced bladder cancer: 'Midsummer Night's Dream' or 'Much Ado About Nothing'? , 1990, British Journal of Cancer.

[5]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Tannock,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.

[7]  D. Skinner.  M-VAC chemotherapy in the management of locally advanced bladder cancer. , 1988, The Journal of urology.

[8]  V. Reuter,et al.  Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. , 1988, The Journal of urology.

[9]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.